In 51 patients with elevated Lp(a) and established cardiovascular disease on regular lipoprotein apheresis, pelacarsen vs placebo for 52 weeks cut the rate of apheresis sessions (0.16 vs 0.93) and lowered Lp(a) by 72%; injection site redness was more common.
RCTn = 51
Parhofer et al. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial